Living Well with Chronic Lymphocytic Leukemia:

Education, Empowerment and Learning from Others
Today’s program is made possible through sponsorship from CLL Global Research Foundation, which received support from AbbVie Inc., Genentech Inc., Gilead Sciences, Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc. and Teva Pharmaceuticals.

In partnership with:
The University of Texas MD Anderson Cancer Center

Produced by:
Patient Power
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:15 AM</td>
<td>What Is CLL and How Does It Progress?</td>
</tr>
<tr>
<td>11:15 – 11:45 AM</td>
<td>Update on the Latest Treatment and Research</td>
</tr>
<tr>
<td>11:45 – 12:15 PM</td>
<td>Monitoring and Treatment Decisions</td>
</tr>
<tr>
<td>12:15 – 12:30 PM</td>
<td>Meet the Patient Panel</td>
</tr>
<tr>
<td>12:30 – 1:00 PM</td>
<td>Breakout Session: Help Me, Help You</td>
</tr>
<tr>
<td>1:00 – 1:30 PM</td>
<td>Lunch Provided</td>
</tr>
<tr>
<td>1:30 – 2:15 PM</td>
<td>Living Well with CLL</td>
</tr>
<tr>
<td>2:15 – 3:00 PM</td>
<td>Q&amp;A Session</td>
</tr>
</tbody>
</table>
Introductions
Understanding CLL

- What is CLL?
- What are the symptoms?
- How does it progress?
Chemotherapy Agents

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorambucil</td>
<td>Leukeran®</td>
</tr>
<tr>
<td>Prednisone</td>
<td>Deltasone ®, Liquid Pred®</td>
</tr>
<tr>
<td>Fludarabine</td>
<td>Fludara®</td>
</tr>
<tr>
<td>Bendamustine</td>
<td>Treanda ®</td>
</tr>
</tbody>
</table>
Current Treatments

• Antibodies
  – Anti-CD52
    • Alemtuzumab (Lemtrada®)
  – Anti-CD20
    • Rituximab (Rituxan®, MabThera®, and Zytux®)
    • Ofatumumab (Arzerra®)
    • Obinutuzumab (GAZYVA®)
Current Treatments

• Inhibitors
  – Ibrutinib (Imbruvica®)
  – Idelalisib (Zydelig®)
Current Treatments

• Combination Therapies
• Stem Cell Transplantation
• Others?
Treatments in Development

• Chemotherapy
  – Lenalidomide (REVLIMID®)

• Immunotherapy/ Monoclonal Antibodies
  – Chimeric Antigen Receptors (CARs)
  – Checkpoint inhibitors (e.g., nivolumab)
  – ISF35
  – Plerixafor
  – Others?
Treatments In Development

Inhibitor Therapies:

- BTK inhibitors
  - fostamatinib
- SyK inhibitors
  - dasatinib
- P13k inhibitors
- Lyn inhibitors
  - bafetinib
- Bcl-2 inhibitors
  - ABT-199
- Others?
Monitoring and Treatment Planning

- What is Watch and Wait?
- What am I "watching" for? What is my doctor "watching" for?
- How do prognostic and genetic factors come into play when choosing treatment?
- What should be considered when choosing treatment?
Monitoring and Treatment Planning

• How is treatment response measured? What is considered success?

• What is my role in my care and treatment? Being active in managing my disease – tracking progress (active surveillance/monitoring)

• Does deciding on one treatment course limit my future options?

• Considering a clinical trial
Online Audience:

*We will return at 1:30 PM Central Time (2:30 PM ET, 11:30 AM PT)*
Living Well with CLL: Communication

• Collaborating with your healthcare team
• Keeping family and friends in the loop
• Communicating at the workplace
Living Well with CLL: Emotional/Mental Health Aspects

- Coping emotionally with "watch and wait"?
- Advice for care partners
- Dealing with anxiety/depression
- Strategies to live the best you can
  - Diet and lifestyle choices that may make a difference
Living Well with CLL: Side Effects

• Overview of common disease symptoms and complications and their treatment
• Communicating with healthcare team about treatment side effects
• Are there secondary cancers or associated conditions that I should be aware of?
• Alternative/complementary medicine
Living Well with CLL: Resources

• Where to find
  – Financial help?
  – CLL specialist?
  – Mental health professionals?

• Affordability of treatment and assistance programs and resources
Thank You

Sponsors:
- AbbVie Inc.
- Genentech Inc.
- Gilead Sciences
- Janssen Pharmaceuticals, Inc.
- Pharmacyclics, Inc.
- Teva Pharmaceuticals

Provided by:
- CLL Global Research Foundation

Partners:
- The University of Texas MD Anderson Cancer Center
- Patient Power

www.cllglobal.org
Share Your Feedback:

How did we do today? Tell us in our survey:
http://sgiz.mobi/s3/f1ff497863b8
Produced by:

Patient Power

For more expert interviews and patient stories throughout the year, and to view this program online, visit: PatientPower.info/CLL

Join the Patient Power community to receive regular CLL news and updates, including videos from this event: PatientPower.info/Join

We want to hear from you, so please feel free to email us at: CLL@patientpower.info